During the past decade, University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "Pfizer" with 1 trials as a collaborator and "University of Rochester" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue" are "Multiple Sclerosis, Relapsing-Remitting" (1 trials), "Parkinson Disease" (1 trials), "Parkinson's Disease" (1 trials) and "Relapsing-remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue" in a lesser frequency.

Most popular intervention types in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Albumin (Human) 25%, United States Pharmacopeia (USP)" (1 trials), "Coenzyme Q10 with vitamin E" (1 trials), "Copaxone®" (1 trials), "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified" (1 trials) and "Rebif®" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue" are 4 trials for "All" genders.

Currently, there are NaN active trials in "University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Vermont , Department of Neurology Given Building C-219 , 89 Beaumont Avenue, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".